NCT03823352已完成2 期
Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Complete blood count measurements according International Working Group (IWG) response criteria
研究概览
简要总结
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
详细描述
The given pilot clinical trial of a medicinal product for medical use, is held to evaluate preliminary efficacy and safety/tolerability profiles of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of relapsed AML after at least 1 chemotherapy regimen or at initial diagnosis when no intensive treatment possible (based on standard criteria).
- •Men and women 18 to 70 years of age.
- •ECOG performance status = 0 or
- •Ability to comply with the study requirements and give written informed consent.
- •Expected survival more than 3 months.
- •Patients with preserved reproductive potential agree to use, with their partner, adequate contraception throughout the study and for 30 days thereafter (contraceptive methods with reliability greater than 90%: cervical caps with spermicide, diaphragms with spermicide, condoms with intravaginal spermicide, non-hormonal intrauterine devices), or true sexual abstinence.
排除标准
- •Acute promyelocytic leukemia (APL).
- •Hemoglobin ≤ 7g/dL or platelet ≤ 50,
- •Abnormal liver and renal function:
- •Total bilirubin > 2 mg/dL;
- •AST and ALT > 2.5 × ULN;
- •Creatinine > 1.5 × ULN, OR creatinine clearance < 50 mL/min/1.73m
- •The subject has not recovered to grade ≤ 1 adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered > 4 weeks prior to study enrollment.
- •Patient who has had in the past 3 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast.
- •Subjects with any serious active infection (i.e., requiring an intravenous antibiotic, antifungal, or antiviral agent).
- •Subjects with known human immunodeficiency virus, active hepatitis B or C.
- •Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise subject safety or interfere with the evaluation of the safety of the study drug.
- •Known or suspected substance abuse or alcohol abuse.
- •Patients with history of seizure disorders or central nervous system leukemia.
- •Patients with uncontrolled, intercurrent illness including, but not limited to, symptomatic neurological illness; active, uncontrolled, systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness/social situations that would limit compliance with study requirements.
- •Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Crohn's disease, malabsorption, or CTCAE Grade > 2 diarrhea of any etiology at baseline.
- •Prior major surgery or trauma within 28 days prior to first dose of study drug.
- •A positive urine pregnancy test (strip) for female patients of childbearing potential.
研究组 & 干预措施
Antroquinonol
Experimental
Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
干预措施: Antroquinonol (Drug)
结局指标
主要结局
Complete blood count measurements according International Working Group (IWG) response criteria
时间窗: 2 weeks
Evaluation of preliminary efficacy profile of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.
次要结局
- Number of Participants alive at 4weeks(4 weeks)
- Number of Participants alive at 24 weeks(24 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of ageThe purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced HIV 1 infected children aged from 3 years to < 6 years and weighing between 10 kg and < 20 kg .MedDRA version: 16.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2008-004630-25-Outside-EU/EEATibotec Pharmaceuticals24
进行中（未招募）
不适用
A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugsHIV-1MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004631-37-Outside-EU/EEATibotec Pharmaceuticals12
进行中（未招募）
1 期
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 years.This trial will be referred to as DIONE.Estudio en Fase II, abierto, para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de DRV/rtv una vez al día en adolescentes infectados por VIH-1 de entre 12 y < 18 años de edad no tratados. Nos referiremos a este estudio como DIONE. - DIONEHIV-1VIH-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-004631-37-ESTibotec Pharmaceuticals12
进行中（未招募）
不适用
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-na?ve HIV 1 infected adolescents aged between 12 and < 18 years - DIONEEUCTR2008-004631-37-ITTIBOTEC PHARMACEUTICALS LTD.12
进行中（未招募）
不适用
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 years. - DIONEHIV-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-004631-37-GBTibotec Pharmaceuticals12